Biotech company and anemia drugmaker Amgen Inc. reported higher than expected third quarter profit Tuesday, helped by sales of its rheumatoid arthritis drug Enbrel, which increased 17%. Profit more than doubled to $1.1 billion, or $1.41 per share, compared to $454 million, or 50 cents per share, in its first quarter led by CEO Robert Bradway.  Revenue for the quarter rose 10% to $4.32 billion.

"Our business has very good momentum," Bradway said in a conference call.

Anemia drug sales

•    Aranesp (darbepoetin alfa) sales decreased 17%

•    Epogen  (epoetin alfa) sales increased 3%, beating expectations.